New York-based IRX Therapeutics announced that it has raised $25 million in a Series A. The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment. IRX researchers are developing a therapy that stimulates a coordinated cellular immune response that can enable a patient's own immune system to fight disease. IRX has reported positive mid-stage data and say they plan to launch a late-stage trial.
- check out IRX's release
ALSO: Canada's Inimex Pharmaceuticals has rounded up $22 million in venture funds to conduct the first clinical trials of its IDR drugs. Report